Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Three leading European Comprehensive Cancer Centres launch an international cooperation at top level

27.08.2008
Three European cancer centres in Paris (Institut Gustave Roussy), Amsterdam (Netherlands Cancer Institute) and in Stockholm (Karolinska Institutet), have joined forces in their battle against cancer.

In a collaborative effort, the European Comprehensive Cancer Centre Alliance (ECCCA) strives to develop and implement innovative strategies to improve cancer cure and reduce treatment related side effects.

With a strong focus on combining rationally designed targeted agents with radiotherapy, ECCCA brings together powerful technological platforms of genomics, proteomics and preclinical evaluation tools to identify promising agents for combined application in early clinical trials.

On September 5th this cooperation will start with an inauguration symposium, organised at the NKI, where ECCCA will present its strategic plan, technical platforms and will announce the first three clinical translational trials that will be activated in the three participating centres.

Innovative trials

The cooperation will start immediately with a number of innovative trials. Each institute has submitted a trial that will be executed in all three institutes. In the trials, findings from the lab are “directly” brought into the clinic for evaluating their clinical efficacy. The combined knowledge and facilities in the field of fundamental, translational and clinical research means that it is possible to make rapid progress in this respect. All three trials are characterized by the combination of innovative radiation techniques with translational research.

Image guided Radiotherapy

The trial of the NKI-AVL is aimed at a new concept in breast-conserving treatment. During this treatment only the tumour, rather than the whole breast, is irradiated. A short irradiation schedule will be applied, while using image-guided techniques with a CT scan on the linear accelerator (Image Guided Accelerated Partial Breast Irradiation). The tumour response to treatment will be measured with PET and MRI spectrometry. Simultaneously, genetic analysis is done on the tumour tissue, whereby the response to the treatment is scored. It is anticipated that by looking at the response, it can be predicted which patients are suitable for this limited short treatment. The genetic changes during the radiation will also indicate which drugs may enhance the cell-killing effect of radiation.

Stereotactic Body radiotherapy (SBRT) in advanced lung cancer as an adjunctive to pharmaceutical treatment

With SBRT, tumours can be irradiated with high precision, sparing damage to surrounding healthy tissue. This technology was pioneered at Karolinska and is now being tested for various tumour indications. In this study, initiated by Karolinska, SBRT will be given to both primary tumours and metastatic locations, followed by conventional chemotherapy. The goal is to control tumours in locations that can be identified by novel imaging techniques (PET/CT). After SBRT the tumour disease will return to a less advanced stage, for which chemotherapy will be more effective. The goal of the treatment is to substantially prolong the patient’s survival and also to counteract tumour related symptoms.

Inhibition of the PI3-kinase/AKT/mTOR axis during Radiotherapy

Of the molecular anomalies identified in non-small cell lung cancer, EGFr mutation or overexpression, mutations of the RAS oncogene or the PTEN tumour suppressor gene are among the most frequently observed. All of these alterations signal through the PI3-kinase/AKT/mTOR pathway, which is critical for tumour escape from radiation induced cell death.

This trial initiated by IGR, aims at combining radiotherapy for locally advanced non small cell cancer (non metastatic,) sequential radio-chemotherapy and everolimus, an inhibitor of mTOR (RAD001). The first objective is to assess the safety of the combination. In parallel, prospective functional and metabolic imaging will be used (angio scanner and PET) to monitor tumour response. Tumour tissue will also be prospectively collected to define molecular patterns of responding tumours.

Ramona Pauwels | alfa
Further information:
http://www.nki.nl

More articles from Health and Medicine:

nachricht Penn studies find promise for innovations in liquid biopsies
30.03.2017 | University of Pennsylvania School of Medicine

nachricht 'On-off switch' brings researchers a step closer to potential HIV vaccine
30.03.2017 | University of Nebraska-Lincoln

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

'On-off switch' brings researchers a step closer to potential HIV vaccine

30.03.2017 | Health and Medicine

Penn studies find promise for innovations in liquid biopsies

30.03.2017 | Health and Medicine

An LED-based device for imaging radiation induced skin damage

30.03.2017 | Medical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>